D&D Pharmatech Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities

<p><a href="https://open-patsnap-com.libproxy1.nus.edu.sg/marketplace/mcp-servers?from=Synapse_SEO_blog3" target="_blank" rel="noopener"><img src="https://synapse-static-patsnap-com.libproxy1.nus.edu.sg/strapi-static/image_92706a9ee1.png" alt="PatSnap MCP servers used for the D&D Pharmatech BD opportunity scan"></a></p><p><strong>This D&D Pharmatech Company BD Opportunity Scan Report was built with PatSnap Life Sciences MCP workflows.</strong> Company & Deal Intelligence MCP connects the organization pipeline, transaction precedents and financial-report signals; Current Awareness MCP tests for recent-event context. The output is a partnering shortlist with owner, stage, evidence package, IP risk, deal precedent and outreach rationale. <a href="https://open-patsnap-com.libproxy1.nus.edu.sg/marketplace/mcp-servers?from=Synapse_SEO_blog3" target="_blank" rel="noopener">Explore the MCP servers used in this report.</a></p><p><em>Decision date: 22 July 2026. This is a screening memorandum for business-development prioritization, not legal, patent, medical or investment advice. “Not returned” means the searched MCP result did not supply a usable record and must not be read as evidence of absence.</em></p><h2>Executive BD thesis</h2><p>D&D Pharmatech is screened as a potential partnering counterparty across asset licensing, regional commercialization, co-development, platform access and evidence-generation structures. The organization pipeline call returned 30 records at the decision date. The lead returned asset is <strong>P4-M01</strong>, associated with a target not returned and Periodontal Diseases, at Phase 2. The immediate objective is to identify a narrow, executable right set and the evidence package required to test strategic fit.</p><p>A high-quality first meeting should confirm the current development owner, decision rights, territory availability, stage definitions, program status, patent ownership, third-party licenses, CMC readiness, clinical evidence, regulatory history and management’s preferred transaction structure. Pipeline size is a starting signal, not a substitute for strategic fit or diligence.</p><h2>Partnering shortlist</h2><table><thead><tr><th>Priority</th><th>Asset / workstream</th><th>Owner</th><th>Stage</th><th>Evidence package</th><th>IP risk screen</th><th>Deal precedent</th><th>Outreach rationale</th></tr></thead><tbody><tr><td>1</td><td><strong>P4-M01</strong></td><td>D&D Pharmatech Co., Ltd.</td><td>Phase 2</td><td>Pipeline record: target not returned; Periodontal Diseases. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index.</td><td>Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate.</td><td>Neuraly and Enigma Biomedical USA announce a Research License and Commercialization Option Agreement for PET Imaging Biomarker, PMI04</td><td>Phase 2 asset with target not returned exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures.</td></tr><tr><td>2</td><td><strong>Pegsebrenatide</strong></td><td>D&D Pharmatech Co., Ltd.</td><td>Phase 2</td><td>Pipeline record: GLP-1R; Alzheimer Disease, Parkinson Disease, Young onset Parkinson disease, Diabetes Mellitus, Type 2. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index.</td><td>Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate.</td><td>D&D Pharmatech's US unit Neuraly to work with NIH, Johns Hopkins for Parkinson's research</td><td>Phase 2 asset with GLP-1R exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures.</td></tr><tr><td>3</td><td><strong>Zabopegdutide</strong></td><td>Neuraly, Inc.</td><td>Phase 2</td><td>Pipeline record: GCGR x GLP-1R; Metabolic Dysfunction Associated Steatohepatitis, Obesity, Diabetes Mellitus, Type 2. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index.</td><td>Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate.</td><td>D&D Pharmatech and Metsera entered into a new agreement for the global license of the injectable triple-G (GLP-1/GIP/GCG triple agonist) DD15</td><td>Phase 2 asset with GCGR x GLP-1R exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures.</td></tr><tr><td>4</td><td><strong>MET-002</strong></td><td>D&D Pharmatech Co., Ltd.</td><td>Phase 1</td><td>Pipeline record: GLP-1R; Obesity. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index.</td><td>Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate.</td><td>Neuraly and Enigma Biomedical USA announce a Research License and Commercialization Option Agreement for PET Imaging Biomarker, PMI04</td><td>Phase 1 asset with GLP-1R exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures.</td></tr><tr><td>5</td><td><strong>PMI-03</strong></td><td>D&D Pharmatech Co., Ltd.</td><td>Phase 1</td><td>Pipeline record: target not returned; Alzheimer Disease, Neuroinflammation, Parkinson Disease. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index.</td><td>Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate.</td><td>D&D Pharmatech's US unit Neuraly to work with NIH, Johns Hopkins for Parkinson's research</td><td>Phase 1 asset with target not returned exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures.</td></tr></tbody></table><p><strong>Shortlist interpretation.</strong> Priority one should receive the fastest outreach only after the returned owner and stage are reconfirmed. Lower-ranked rows preserve option value and may support a regional license, co-development collaboration, asset carve-out, structured option, research partnership or financing-linked agreement. Any mismatch among asset name, owner, indication and stage is itself a diligence signal that may reflect a transfer, dormant program, territory split or portfolio reprioritization.</p><p><a href="https://open-patsnap-com.libproxy1.nus.edu.sg/marketplace/mcp-servers?from=Synapse_SEO_blog3" target="_blank" rel="noopener"><img src="https://synapse-static-patsnap-com.libproxy1.nus.edu.sg/strapi-static/image_2ed6f2cf76.png" alt="PatSnap Life Sciences MCP workflow for D&D Pharmatech"></a></p><h2>Pipeline and evidence-package readout</h2><p>The organization pipeline fetch anchors asset identity, target, indication and development stage when those fields are returned. Reconcile them against the sponsor’s current presentation, trial registry, regulatory correspondence and data-room index. For each shortlisted asset, request protocol history, enrollment and discontinuation data, endpoint definitions, biomarker strategy, subgroup results, safety narratives, manufacturing comparability, stability data, health-authority feedback and the sponsor’s integrated development plan.</p><p>Evidence quality is strongest when asset identity, stage, owner and indication are mutually consistent across the company record, trial registries and regulatory sources. A stage label should be translated into a milestone map with dates, endpoints, decision gates and remaining cost. Where the MCP result is missing or ambiguous, do not fill the gap by assumption: make the refresh and reconciliation an explicit condition before valuation.</p><h2>Deal precedents and structure signals</h2><table><thead><tr><th>Date</th><th>Transaction</th><th>Status</th><th>Disclosed economics</th></tr></thead><tbody><tr><td>2025-01-17</td><td>Neuraly and Enigma Biomedical USA announce a Research License and Commercialization Option Agreement for PET Imaging Biomarker, PMI04</td><td>Active</td><td>Not disclosed</td></tr><tr><td>2024-07-12</td><td>D&D Pharmatech's US unit Neuraly to work with NIH, Johns Hopkins for Parkinson's research</td><td>Active</td><td>Not disclosed</td></tr><tr><td>2024-03-18</td><td>D&D Pharmatech and Metsera entered into a new agreement for the global license of the injectable triple-G (GLP-1/GIP/GCG triple agonist) DD15</td><td>Active</td><td>Not disclosed</td></tr></tbody></table><p>Transaction precedents guide structure rather than mechanically determine price. Normalize every comparison for stage, territory, modality, included indications, opt-in rights, cost sharing, manufacturing obligations, royalties, milestones, sublicensing, governance, termination and change-of-control provisions. Undisclosed economics can still reveal counterparties, strategic intent and preferred transaction form. A missing search result should trigger a broader licensor/licensee and asset-level search before negotiation.</p><h2>Financial capacity and partnering pressure</h2><ul><li><strong>D&D Pharmatech - Annual Report(2024.12)</strong>: D&D Pharmatech - Annual Report(2024.12) 2) 개발 현황 및 경쟁력 당사는 보고서 제출일 현재 생산 및 판매 중인 제품이 없어 원재료 및 부재료의 매입이 존재 하지 않습니다. 신약연구개발업의 특성상 매입품목은 다양한 종류의 외주 시험서비스와 시 약 및 실험 소모품 등이며, 공급의 독과점이나 안정성에는 문제가 없습니다. 프로젝트 별 특성에 따라 당사와 종속회사 사이에 일부 연구개발 위탁 거래 등이 존재하며, 관련 사항은 주석 'III. 재무에 관한 사항, 5. 재무제표 주석, 29. 특수관계자거래, (2)매출 및 매입 등 거래' 를 참조하시기 바랍니다. (3) 원재료 가격 변동 추이 바이오의약품 연구개발에 사용되는 연구용 시약 및 실험소모품 등은 대부분 장기간 동안 반 복 구매를 하게 됩니다. 일반적으로 원재료의 경우 국내 대리상을 통해 구입하고 있으며 해 외에서 조달하는 원재료의 주요한 가격변동 요인은 환율변동이며, 원재료 등에 대한 개별단 가는 연간 총매입수량 등과 연계되어 매년 가격조정이 이루어지고 있습니다. 나. 생산 및 생산설비에 관한 사항 당사는 연구개발업을 영위하는 회사이기 때문에 대규모 생산설비를 갖추고 있지 않으며, 전 임상 연구 및 임상용 신약후보물질의 생산을 GMP 등의 국제기준을 충족하는 제조전문 위탁 업체(CMO)를 통해 위탁 생산하고 있습니다. 당사의 주요 시설 및 기계장치는 본사 및 종속기업의 연구소에서 신약후보물질 도출 및 연구 개발 목적으로 사용되고 있으며, 시설 및 기계장치의 관한 사항은 'III. 재무에 관한 사항 - 3. 연결재무제표 주석, 10. 유형자산 '을 참조하시기 바랍니다. (기준일: 보고서 작성일 기준) 4. Status of sales and orders D&D Pharmatech - Annual Report</li><li><strong>D&D Pharmatech - [Correction of statement]Prospectus</strong>: D&D Pharmatech - [Correction of statement]Prospectus 2. 자금의 사용목적 주1) 동사의 파트너링 이후 단계의 외부 연구개발비는 추정손익계산에 반영되지 않아 표기하지 않았습니 다. 주2) 증권신고서 제출일 현재 이미 완료된 DD01 전임상과 임상 1상 비용의 경우, 실제 발생한 임상비용을 기입하였습니다. 또한, 각 연도별 추정손익계산에 반영된 외부 연구개발비는 아래와 같습니다. 동사는 예상되 는 임상 비용 중 일부를 공모자금으로 충당하며, 나머지 임상시험비는 내부 자금으로 사용할 계획입니다. 【 외부 연구개발비 연도별 반영 】 주) 2023년도에 실제 발생된 임상 1상 비용 및 임상 2상에 소요될 것으로 예상되는 비용을 합 산한 금액입니다. (2) 운영자금 (단위: 백만원) 운영자금은 임직원의 인건비 및 일반 경영관리비로 구성되어 있으며, 이를 공모자금으로 충 당할 계획입니다. 당사는 2027년 까지의 연결 기준 전사 인력운영계획을 기준으로 하여, 연 평균 인원에 각 직급별 연봉 테이블과 각 국가별 임금상승율을 곱하여 산정하는 방식으로 당 사의 예상 급여 비용을 산정하였습니다. 아래는 회계적 관점에서 구분한 인력 운영 계획으로, 하기 인원에 대한 인건비 중 일부가 공모를 통한 운영자금으로 충당될 예정입니다. 【 부문별 인원 추정 】 전자공시시스템 dart.fss.or.kr ■ 정정 후 가. 자금의 사용계획 증권신고서 제출일 현재 당사의 공모자금 사용계획은 아래와 같습니다. 다만, 하기 투자계획 은 현 시점에서 예상되는 계획이며, 향후 집행 시점의 경영환경 등을 고려하여 변경될 가능 성이 있으므로 절대적인 계획이 아님을 투자자께서는 인지하시기 바랍니다. D&D Pharmatech - [Correction of statement]Prospectus</li><li><strong>D&D Pharmatech - Quarterly Report(2024.09)</strong>: D&D Pharmatech - Quarterly Report(2024.09) 4. 매출 및 수주상황 당사는 기술이전 계약을 위한 잠재적 파트너사 후보업체를 지속적으로 발굴, 접촉하고 있으 며, 이를 위해 JP 모건 헬스케어 컨퍼런스, 바이오 USA, 바이오 유럽, China 바이오 등 주요 국제 바이오 컨퍼런스에 지속적으로 참석하고 있습니다. 또한, 필요에 따라 로컬 비즈니스 네 트워크가 있는 파트너링 중개 에이전시를 통해서도 기회의 폭을 넓히는 노력을 하고 있습니 다. 내부 사업개발팀에서는 시장 및 경쟁상황 변화에 따라 각 품목에 맞는 파트너링 전략을 수시 로 업데이트 하고 있으며, 기존 접촉했던 업체들에게도 제품 개발 진척에 따른 정보를 지속 적으로 업데이트 해주면서 관심도를 증강시키고 당사의 개발역량에 대한 신뢰도를 높이는 작업들을 꾸준히 진행하고 있습니다. 이렇게 다져진 신뢰도를 바탕으로 단순 기술이전(라이 선스 아웃)을 넘어 공동개발, 조인트벤처 등 다양한 파트너링 협력 구조로 사업개발 기회를 넓혀가고 있습니다. 다. 판매전략 당사는 파이프라인 별 상용화(기술이전 등 파트너링) 전략을 가지고 있으며, (1) 당사의 주력 제품이며 시장 잠재력이 큰 제품에 대해서는 인체에서의 유효성(PoC)을 확인 후 파트너링을 진행하여 가치를 극대화하고, (2) 당사의 역량이 제한적인 제품에 대해서는 초기에 빠른 기 술이전을 진행하여 개발 비용 절감 및 리스크를 줄이는 것을 기본 전략으로 하고 있습니다. 이를 위해, 각 제품별 타겟 시장의 변화와 경쟁상황을 주기적으로 통합 분석하여 제품의 경 쟁 포지셔닝을 업데이트하고 있으며, 그에 맞는 타겟 제품 프로파일(Target Product Profile)도 조정하여 파트너사에 어필될 수 있는 포인트로 사업기회 논의를 진행하고 있습니 다. D&D Ph</li></ul><p>Translate financial signals into BD questions. Confirm unrestricted cash, quarterly operating use, committed trials, debt and royalty financing, covenant constraints, near-term milestone receipts, commercial investment and management’s minimum runway threshold. A well-capitalized company may prefer a premium strategic collaboration; a constrained company may prioritize non-dilutive funding, regional monetization, cost sharing or a staged option.</p><h2>Current-awareness events and outreach triggers</h2><p>The Current Awareness <code>news_search</code> call did not return a parseable recent-event record at the decision date. Refresh the search before outreach and reconcile press releases, trial updates, regulatory events, financing announcements, management changes and partnering disclosures. Do not interpret the missing return as absence of news.</p><p>The best outreach window often follows a data readout, regulatory interaction, financing, portfolio review, leadership change or new transaction. Build a trigger calendar and identify the person who owns the asset, the therapeutic-area BD lead, the regional commercial lead and alliance-management stakeholders. Outreach should cite one verified event and one specific contribution the prospective partner can make.</p><h2>IP and freedom-to-operate risk screen</h2><p>The IP review is a gating workstream, not a footnote. Request the full patent-family schedule, inventorship and assignment history, prosecution status, expected expiries, patent-term adjustment or extension assumptions, opposition and litigation history, third-party licenses, field and territory restrictions, royalties, reach-through clauses, government rights and material-transfer obligations. Map composition-of-matter, method-of-use, formulation, manufacturing, biomarker, combination, platform and delivery claims to the exact rights proposed in the deal.</p><p>Screen risk as medium by default when an asset and owner are returned but the patent package has not been reviewed; elevate it to high where ownership, stage or program status is not returned. A license must match patents, know-how, data, regulatory references, materials, manufacturing rights and sublicensing rights to the precise field and geography. Complete a claim-level patent and FTO review before exclusivity, valuation or term-sheet approval.</p><h2>Recommended deal structures</h2><ul><li><strong>Regional license:</strong> useful when development or commercial capabilities differ by territory; define data access, regulatory responsibilities, supply, transfer pricing and reversion rights.</li><li><strong>Co-development:</strong> appropriate when both parties contribute clinical, biomarker, regulatory or commercial capabilities; specify cost sharing, governance, global strategy and opt-out economics.</li><li><strong>Option-to-license:</strong> reduces uncertainty before a defined data event; specify option fee, exercise trigger, diligence standard, exclusivity period and pre-agreed economics.</li><li><strong>Research or platform collaboration:</strong> suitable when the value resides in discovery or delivery capability; define targets, ownership of foreground IP, publication, replacement rights and downstream options.</li><li><strong>Structured financing:</strong> may combine equity, milestone funding, royalties or territory monetization; test covenant, accounting, control and change-of-control implications.</li></ul><h2>Outreach rationale and first-contact plan</h2><ol><li><strong>Identify the decision owner.</strong> Map the asset team, corporate-development lead, therapeutic-area leadership, regional commercial lead and alliance-management stakeholders.</li><li><strong>Lead with one verifiable gap.</strong> Focus on territory, evidence, diagnostics, manufacturing, delivery, financing or combination strategy rather than a generic partnership request.</li><li><strong>Attach a concise evidence package.</strong> Include the returned stage, indication footprint, relevant transaction precedent, partner contribution, proposed work plan and decision gates.</li><li><strong>Offer a structure.</strong> Present one primary and one fallback structure with clear rights, funding, governance and diligence assumptions.</li><li><strong>Define the diligence sequence.</strong> Request data-room access, IP/FTO materials, CMC documents, safety data, regulatory correspondence, economics and encumbrances before exclusivity.</li></ol><h2>Decision memo</h2><p><strong>ADVANCE TARGETED OUTREACH, SUBJECT TO EVIDENCE REFRESH.</strong> D&D Pharmatech offers a credible screening case because the MCP workflow identifies either a returned pipeline opportunity or a concrete set of evidence gaps that can be tested rapidly. The first contact should be tailored to a named asset where available, quantify the partner’s contribution, acknowledge IP and execution risks and avoid using pipeline count as a proxy for value.</p><p><strong>Required next diligence:</strong> refresh all four MCP searches; fetch full deal records for economics and rights; reconcile the newest financial filing and public event disclosures; verify owner and license chain; obtain patent-family and FTO work; review CMC, safety and regulatory materials; and model risk-adjusted economics by indication, territory and transaction structure.</p><p><a href="https://open-patsnap-com.libproxy1.nus.edu.sg/marketplace/mcp-servers?from=Synapse_SEO_blog3" target="_blank" rel="noopener"><img src="https://synapse-static-patsnap-com.libproxy1.nus.edu.sg/strapi-static/image_dddd7a2c83.png" alt="Explore PatSnap MCP servers for D&D Pharmatech partnering intelligence"></a></p><p><a href="https://open-patsnap-com.libproxy1.nus.edu.sg/marketplace/mcp-servers?from=Synapse_SEO_blog3" target="_blank" rel="noopener"><strong>Explore PatSnap Open Platform MCP Servers and build your next biopharma BD workflow.</strong></a></p><hr><p><strong>Data provenance:</strong> PatSnap Company & Deal Intelligence MCP (<code>organization_pipeline_fetch</code>, <code>drug_deal_search</code>, <code>financial_report_search</code>) and Current Awareness MCP (<code>news_search</code>); accessed 22 July 2026. Counts, ownership and statuses may change as records update.</p>